Streetbeat News

Stock Prices

EPAM

Susquehanna analyst James E Friedman reiterated a Positive rating on EPAM Systems (NYSE:EPAM) but lowered the price target to $300 from $350 due to reduced forecasts. EPAM recently slashed its 2Q23 and FY23 financial outlook due to weakness in near-term demand. However, the analyst believes the current slowdown is likely temporary.

Portfolio Pulse from Nabaparna Bhattacharya

June 09, 2023 | 6:33 pm

BEKE

KE Holdings shares are trading lower after gaining on Thursday, indicating a pullback in the stock.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 6:32 pm

Z

ZG

Zillow shares are trading lower without any company-specific news.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 6:31 pm

PL

Needham analyst Ryan Koontz reiterated a Buy rating on Planet Labs (NYSE:PL) with a price target of $8. The company posted solid 1Q24 results but reduced its F2Q and F24 outlook due to macro headwinds. Revenue was $52.7 million, driven by the Defense and Intelligence segment. PL is seen as the emerging leader in global earth observation.

Portfolio Pulse from Shivani Kumaresan

June 09, 2023 | 6:31 pm

KEYS

Keysight Techs (NYSE:KEYS) has outperformed the market over the past 5 years, producing an average annual return of 21.34%. A $1000 investment in KEYS 5 years ago would be worth $2,626.52 today.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 6:30 pm

ITW

Illinois Tool Works (NYSE:ITW) has outperformed the market over the past 15 years, producing an average annual return of 11.0%. A $100 investment in ITW 15 years ago would be worth $476.23 today.

Portfolio Pulse from Benzinga Insights

June 09, 2023 | 6:30 pm

ETSY

Etsy shares are trading higher after JMP Securities maintained a Market Outperform rating and a $130 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

June 09, 2023 | 6:28 pm

BLUE

CRSP

VRTX

The FDA has accepted Vertex Pharmaceuticals and CRISPR Therapeutics' exa-cel application for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). Priority review has been granted for SCD, while standard review has been granted for TDT. Analysts maintain positive ratings on CRISPR Therapeutics.

Portfolio Pulse from Vandana Singh

June 09, 2023 | 6:08 pm

BLNK

Blink Charging (BLNK) sees a surge in Sep 15 $9 call options near the ask with 1024 contracts at $0.25, compared to 899 open interest. Earnings are expected on 8/7 after the market close.

Portfolio Pulse from Charles Gross

June 09, 2023 | 6:07 pm

DRS

Truist Securities analyst Michael Ciarmoli initiated coverage on Leonardo DRS Inc (NASDAQ:DRS) with a Buy rating and a price target of $19. Ciarmoli is bullish on DRS' exposure to next-generation systems but cautious about management's ability to benefit from RADA acquisition and changes in US defense spending.

Portfolio Pulse from Lekha Gupta

June 09, 2023 | 6:03 pm